Skip to main content

Security report for biogen.dk

Biogen (Denmark) A/S · Healthcare · Denmark

Low risk. 2 critical or high findings in Email security and SSL/TLS.

Security score

78/100

Risk levelLow

0–100, higher is better. How it is calculated

Biogen (Denmark) A/S is a leading global biotechnology company focused on innovative research and development of treatments for serious and complex diseases, including neurological, neuropsychiatric, immunological, and rare diseases. The website reflects a professional corporate presence targeting healthcare professionals, patients, and potential employees. The company positions itself as a pioneer in healthcare innovation with a commitment to improving patient lives and societal health. Technically, the website is built on Adobe Experience Manager CMS, utilizing modern JavaScript libraries such as jQuery and Adobe Helix RUM for performance monitoring. It employs Google Analytics and Google Tag Manager for user analytics and tracking, complemented by a comprehensive cookie consent mechanism compliant with GDPR requirements. Security posture is strong with HTTPS enforced and use of secure cookies, though the absence of explicit security policies and incident response information is noted. The lack of WHOIS data for the domain slightly reduces trustworthiness but does not detract significantly from the overall legitimacy given the professional content and branding. Strategic recommendations include enhancing security headers, publishing security and incident response policies, and improving accessibility compliance.

Scanned

NIS2 and GDPR posture

GDPR outside view
83/ 100 · Low
Checks completed
7of 7

NIS2 Art. 21(2)

  1. (a) Risk analysis and security policies: Not visible from outside
  2. (b) Incident handling: One indicator
  3. (c) Business continuity, backups and crisis management: Not visible from outside
  4. (d) Supply chain security: Not visible from outside
  5. (e) Secure acquisition, development and maintenance, including vulnerability handling: Partly checked
  6. (f) Assessing the effectiveness of security measures: Not visible from outside
  7. (g) Cyber hygiene and security training: Not visible from outside
  8. (h) Cryptography and encryption: Partly checked
  9. (i) HR security, access control and asset management: One indicator
  10. (j) Multi-factor authentication and secured communications: Not visible from outside

This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.

GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.

Priority findings

2 findings rated critical or high. Fix these first.

  1. Email security

    SPF, DKIM and DMARC stop others sending email that looks like it comes from your domain, a common route to phishing and invoice fraud.

    • Critical

      No email authentication configured

      Domain is vulnerable to email spoofing

      What to do: Implement SPF, DKIM, and DMARC immediately

  2. SSL/TLS

    TLS encrypts the connection and proves the site is really yours. Weak or expiring certificates trigger browser warnings and put traffic at risk.

    • High

      Weak Protocols Supported

      Server supports weak protocols: TLSv1.1

      What to do: Disable TLS 1.0, TLS 1.1, and all SSL versions

      • CWE-327
      • OWASP A04:2025
      • ASVS V12.1.1

Need hands-on remediation? Email guard@offseq.com

Keep watching biogen.dk

This scan found 19 issues across 6 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.

Daily monitoring

Recommended

€25per month

  • TLS certificates and expiry
  • DNS records
  • SPF, DKIM and DMARC
  • Security headers
  • GDPR and NIS2 posture
  • Exposed services
  • Third-party trackers
  • Security score drift

Email alerts on material changes and an exportable JSON history of every change.

Billed monthly to your card. Cancel anytime. The full timeline opens with your unlock code.

Full report

€39.90one-time

  • The complete analysis as a PDF you can cite
  • Email delivery with an unlock code
  • Lifetime access to this report

Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.

Results by check

Each check with its score, findings and the evidence it collected.

How this score is calculated

The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.

Counted in this score

SSL/TLS
72
Security headers
95
Email security
60
DNS health
60
Network security
100
GDPR outside view
83
Average
78

Not counted

  • NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
  • OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.

Findings that cap the score at 49

Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.

  • The certificate is not trusted by browsers
  • The website is not served over HTTPS
  • A database, remote desktop, file-sharing or Telnet service is reachable from the internet
  • The page loads a script from a compromised source
  • The domain registration has expired
  • SPF authorises every server to send mail as the domain

Partial scans

When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.

Risk levels

  • Critical0–25
  • High26–49
  • Medium50–75
  • Low76–100

Breach exposure

Leaked credentials and lookalike domains from OffSeq Breach. The counts are free; the detailed lists are paid add-ons.

Dark web exposure

Add-on

Leaked records that mention biogen.dk, from OffSeq Breach.

No leaked records found

Breach holds no records for biogen.dk right now. New leaks arrive continuously, so monitoring on Breach alerts you if that changes.

Monitor on Breach (opens in a new tab)

Technical appendix

Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.

Business context

Business profile

Biogen operates in the healthcare biotechnology sector with a large enterprise footprint in Denmark and globally. The company’s business model centers on research-driven development of pharmaceutical treatments for complex diseases, targeting both healthcare providers and patients. The website supports multiple languages and regions, indicating a broad international presence. The company leverages digital marketing and analytics tools to optimize user engagement and compliance with privacy regulations. Social media integration and detailed cookie management reflect a mature digital strategy. The absence of direct contact information on the homepage suggests a controlled communication channel, likely routed through dedicated corporate contacts elsewhere. The missing WHOIS data is unusual but may be due to local registry policies or privacy controls. Overall, Biogen demonstrates strong market positioning and operational maturity.

Security posture

The website enforces HTTPS and uses secure, httpOnly cookies to protect session integrity and prevent cross-site request forgery. Cookie consent is managed via Cookiebot with granular user controls, supporting GDPR compliance. Google Analytics is configured with IP anonymization. However, the site lacks visible security headers such as Content-Security-Policy and X-Frame-Options, which are recommended to mitigate common web vulnerabilities. No explicit security or incident response policies are published, and no dedicated security contact channels are provided. No vulnerabilities or exposed sensitive data were detected in the HTML content. The security score is good but could be improved by implementing recommended headers and publishing security governance information.

Recommendations

  1. Implement HTTP security headers including Content-Security-Policy, X-Frame-Options, and X-Content-Type-Options to enhance protection against common web attacks.
  2. Publish a dedicated security policy and incident response page with clear contact information for reporting security issues.
  3. Regularly audit and update third-party scripts and libraries to mitigate potential vulnerabilities.
  4. Improve website accessibility compliance to ensure inclusivity and meet legal standards.
  5. Enhance transparency by providing more detailed business contact information and corporate governance disclosures.
Site observations

Automated reading of the public site. Ratings are indicative.

Business

Company
Biogen (Denmark) A/S
Description
Biogen er en førende global biotek-virksomhed med fokus på innovativ forskning indenfor alvorlige og komplekse sygdomsområder. Biogens pipeline omfatter potentielle behandlinger indenfor neurologi, neuropsykiatri, immunologi og sjældne sygdomme. Vores ambition er at gøre en forskel for mennesker og samtidig fremme en sundere, mere bæredygtig og retfærdig verden.
Key services
Innovative research, Development of treatments for neurological, neuropsychiatric, immunological, and rare diseases
Content quality
good
Branding
consistent

Technology

Stack
jQuery 3.6.4, Adobe Helix RUM, Cookiebot, Google Tag Manager, Google Analytics
Frameworks
Adobe Experience Manager (AEM)
Performance
moderate
Mobile
good
Accessibility
basic
SEO
good

Security

Observed score
85/100
Good practices seen
  • HTTPS enforced
  • Cookie consent banner with granular controls
  • Use of httpOnly cookies for security
  • Load balancing cookies for performance

Analytics and tracking

Services
Google Analytics
Tracking level
moderate
Privacy practices
good

Advertising

Tracking pixels
Cookiebot session tracker
Marketing tools
Cookiebot
Transparency
good

Site quality

Design
good
User experience
good
Content relevance
good
Navigation
good
Professionalism
good
Trustworthiness
high

Key observations

  1. Website is fully accessible with rich content in Danish language.
  2. Strong cookie consent mechanism with detailed cookie categories and user controls.
  3. No direct contact emails or phone numbers found on the homepage or footer.
  4. Social media links are present and point to official Biogen accounts.
  5. No explicit security or incident response policies published on the site.
  6. WHOIS data is missing or unavailable, which is unusual for a corporate domain.
  7. Website uses Adobe Experience Manager CMS and modern JavaScript libraries.
  8. Google Analytics and Google Tag Manager are used for analytics and tracking.
  9. No signs of adult or unsafe content detected.
Technical notes

Notes

The website is built on Adobe Experience Manager CMS, a robust enterprise platform suitable for large organizations. It uses modern JavaScript libraries including jQuery 3.6.4 and Adobe Helix RUM for real user monitoring. Google Tag Manager and Google Analytics are integrated for analytics and marketing purposes, with cookie consent managed by Cookiebot. The site is mobile responsive with good navigation clarity and SEO optimization. Performance is moderate, with video content and rich media assets present. No critical technical issues or broken elements were detected. Opportunities exist to improve accessibility and implement additional security headers to reduce technical risk.
Standards and sources

Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.

Retrieved 2026-10-25

Reviews of this site

Share your experience with biogen.dk. Every review is verified by email and published after moderation.

Overall rating
Select a rating
4000 characters remaining

We’ll email you to confirm your review and keep your details private.

Community rating

No published reviews yet. Be the first to review biogen.dk.

Feedback on this report

Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.

Overall report quality
Select a rating
2000 characters remaining

We only use your feedback to improve Guard reports. Contact details are never shared.